Centre National De La Recherche Scientifique

Institut Pasteur

Centre Nationale De La Recherche Scientifique

Abraxis, Inc.

Jordi Molgo

Philippe Brulet

Julien Barbier

Hoang-Oanh Nghiem

Reto Stöcklin

Romulo Araoz

Luis Botana

Natalia Vilarino

Philippe Favreau

Evelyne Benoit

Sylvie Roux

Cécile Saint Cloment

Christian Bloy

Cesar Mattei

Cécile Institut Pasteur Saint Cloment

The pr&#xe9;sent invention relates to a method for manufacturing an analysis device including torp&#xe9;do membrane fragments immobilized at the surface thereof, to the resulting analysis device, and to the use of said device for detecting, purifying, and characterizing mol&#xe9;cules acting on nicotinic acetylcholine receptors. The pr&#xe9;sent invention is useful in the field of monitoring seafood, monitoring neurotoxic phytoplankton for the shellfish industry, monitoring the quality of bathing waters along tourist beaches, the field of monitoring fresh water reserves, the field of m&#xe9;dical research, the field of the biological analysis and characterization of mol&#xe9;cules, e.g., non-radioactive assays of the movement of the ligand-receptor bond on an ELISA-type microplate, thereby enabling comp&#xe9;titive agonists and antagonists of targets to be detected, e.g., of highly sensitive receptors.

Method for manufacturing an analysis substrate, and use thereof for detecting toxins

The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.

Mu-conotoxin peptides and use thereof as a local anesthetic

A hybrid protein (GFP-TTC) comprising the non-toxic proteolytic C fragment of tetanus toxin fused to green fluorescent protein was used to analyze the functional synaptic organization of neural networks. When injected intramuscularly in vivo, the GFP-TTC hybrid protein binds to tetanus neurotoxin receptors and clusters very rapidly to the active neuromuscular junction. Membrane traffic by GFP-TTC at the pre-synaptic level of the neuromuscular junction is strongly and rapidly influenced by exogenously co-injecting neurotrophic factors, such as BDNF, NT-4, and GDNF, but not by NGF, NT-3, and CNTF. The membrane traffic, directly detected using GFP-TTC in vivo, permits methods of analyzing synaptic functioning as well as methods of modulating neuronal transport using neurotrophic factors and agonists or antagonists thereof.

In vivo modulation of neuronal transport

The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone derivatives, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.

Methods for treating glutamate cytotoxicity with beta-naphthoquinone compounds

Growing community of inventors

Paris, France

Jordi Molgo